Nestlé Replaces Failed Ulcerative Colitis Program
This article was originally published in Scrip
Nestlé's pharmaceutical arm, Nestlé Health Science, has licensed an ulcerative colitis treatment candidate from Lipid Therapeutics. It plans to start a Phase III trial with it in the US in 2016.
Register for our free email digests: